摘要
三阴性乳腺癌作为乳腺癌的一种特殊亚型,对内分泌治疗和现有靶向治疗无效,并且通常复发较早、进展迅速、预后较差。现就三阴性乳腺癌的分子分型及其临床价值、化疗药物和化疗方案以及化疗和潜在的新靶点药物联合方面的最新进展作一综述。
Triple negative breast cancer （TNBC）, as a special molecular subtype of breast cancer, is non-responsive to endocrine therapy or commercially available targeted therapy. It is characterized by early recurrence, rapid progression and poor prognosis. This systemic and comprehensive overview was focused on recent progress on molecular subtyping of triple negative breast cancer and its possible clinical value, chemotherapeutic agents and chemotherapy regimens, and combination of chemotherapy with potential molecular targeting agents.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2014年第4期316-320,共5页
China Oncology
基金
国家自然科学基金面上项目(No:81372846)
上海市卫生局科研项目(No:沪卫科教201049)
关键词
三阴性乳腺癌
分子分型
新辅助化疗
辅助化疗
姑息化疗
Triple negative breast cancer
Molecular subtypes
Neoadjuvant chemotherapy
Adjuvant chemotherapy
Palliative chemotherapy
